Who are Canesten®'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Monistat, Ketoconazole 2% Shampoo, clotrimazole vaginal tablets, Bifonazole Cream, Ketoconazole 2%, Clotrimazole 1%.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/canesten.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Canesten® — Competitive Intelligence Brief

Canesten® (Canesten®) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Imidazole antifungal. Area: Infectious Disease.

marketed Imidazole antifungal Lanosterol 14α-demethylase (CYP51) Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Canesten® (Canesten®) — Ache Laboratorios Farmaceuticos S.A.. Canesten inhibits fungal cell membrane synthesis by blocking ergosterol production through inhibition of lanosterol 14α-demethylase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Canesten® TARGET	Canesten®	Ache Laboratorios Farmaceuticos S.A.	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Monistat	miconazole	Johnson & Johnson (Janssen)	marketed	Imidazole antifungal	7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6	1974-01-01
Ketoconazole 2% Shampoo	Ketoconazole 2% Shampoo	Fakultas Kedokteran Universitas Indonesia	marketed	Imidazole antifungal	Fungal cytochrome P450 (CYP51 / lanosterol 14α-demethylase)
clotrimazole vaginal tablets	clotrimazole vaginal tablets	Peking University Shenzhen Hospital	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Bifonazole Cream	Bifonazole Cream	Galderma R&D	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Ketoconazole 2%	Ketoconazole 2%	University of California, Davis	marketed	Imidazole antifungal	Fungal cytochrome P450 (CYP51 / lanosterol 14α-demethylase)
Clotrimazole 1%	Clotrimazole 1%	Jinnah Postgraduate Medical Centre	marketed	Imidazole antifungal	Fungal cytochrome P450 (lanosterol 14α-demethylase)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Imidazole antifungal class)

Galderma R&D · 2 drugs in this class
Bayer · 2 drugs in this class
AmDerma · 2 drugs in this class
Jinnah Postgraduate Medical Centre · 2 drugs in this class
Ache Laboratorios Farmaceuticos S.A. · 2 drugs in this class
Jamaica Hospital Medical Center · 1 drug in this class
Johnson & Johnson (Janssen) · 1 drug in this class
Laboratoire Innotech International · 1 drug in this class
PAEC General Hospital, Islamabad · 1 drug in this class
Peking University Shenzhen Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Canesten® — Competitive Intelligence Brief. https://druglandscape.com/ci/canesten. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab